methyl ethyl-L-prolinate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl ethyl-L-prolinate
• 英文别名: N-ethyl-L-proline methyl ester；Methyl (S)-1-ethyl-2-pyrrolidinecarboxylate；Ethylproline methyl ester；methyl (2S)-1-ethylpyrrolidine-2-carboxylate
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: QHWKVODROGDHIE-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl ethyl-L-prolinate 在 β-环糊精 、 2-碘酰基苯甲酸 作用下， 以 水 为溶剂， 反应 6.0h， 以71%的产率得到甲基1-乙基-1H-吡咯-2-羧酸酯
  参考文献：
  名称：

  o-Iodoxybenzoic acid (IBX): a versatile reagent for the synthesis of N-substituted pyrroles mediated by β-cyclodextrin in water

  摘要：

  o-Iodoxybenzoic acid (IBX), a very mild and efficient hypervalent iodine(V) reagent, aromatizes diversely substituted 1-benzylpyrrolidines and N-substituted L-proline analogues to the corresponding substituted pyrroles in good to excellent yields under mild conditions mediated by beta-cyclodextrin in water at room temperature. To the best of our knowledge, this is the first report on IBX, promoting complete aromatization leading to N-benzylpyrroles from the corresponding saturated five membered heterocyclic derivatives in water medium. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.06.077
• 作为产物：
  描述：

  L-脯氨酸甲酯盐酸盐 、 甲磺酸乙酯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以33%的产率得到methyl ethyl-L-prolinate
  参考文献：
  名称：

  [EN] EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF
  [FR] ANTAGONISTES PEPTIDIQUES CYCLIQUES DE L'EPHA4 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本文揭示了化合物及其使用方法，用于调节EphA4受体活性。在一个方面，提供了一种治疗或预防由EphA4介导的疾病或紊乱的方法，包括向需要的受试者施用本文描述的化合物的治疗有效量，包括某些实施例，或结构式(I)，(l-A)，(II)，(III)，(IV)，(IV-1)，(V)，(Vl-A)，(Vl-B)，(VII-1)，(VII-2)，(VIII-1)，或(VIII-2)，或其对映体，对映体混合物，两个或更多对映异构体混合物，或其同位素变体；或其药学上可接受的盐，溶剂合物或水合物。

  公开号：

  WO2019213620A1

文献信息

• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：REDX PHARMA PLC

  公开号：WO2017046606A1

  公开（公告）日：2017-03-23

  This invention relates to antibacterial and antimycobacterial drug compounds of formula (I). It also relates to pharmaceutical formulations of antibacterial drug compounds of formula (I). It also relates to uses of the derivatives in treating bacterial infections and to methods of treating bacterial infections. The compounds are particularly useful for treating bacterial infections that have developed resistance to other drug compounds, e.g. resistant strains of S. aureus.

  本发明涉及公式（I）的抗菌和抗分枝杆菌药物化合物。它还涉及公式（I）的抗菌药物化合物的制药配方。它还涉及利用这些衍生物治疗细菌感染的用途以及治疗细菌感染的方法。这些化合物特别适用于治疗对其他药物化合物产生抗药性的细菌感染，例如金黄色葡萄球菌的耐药菌株。
• Efficient stereoconservative synthesis of 1-substituted (S)- and
  申请人：Astra Lakemedel Aktiebolag

  公开号：US05300660A1

  公开（公告）日：1994-04-05

  Stereoconservative method for preparation of an (R)- or (S)-isomer of the compound of the formula I with at least 95% optical purity ##STR1## wherein R.sup.1 is a hydrogen atom, a saturated or unsaturated lower alkyl group, a cycloalkyl group, or a group (CH.sub.2).sub.m Ph wherein m is 0-3 and Ph is a substituted or unsubstituted phenyl group including 1) O,N-dialkylation, directly or stepwise of (R)- or (S)-proline 2) aminolysis 3) reduction to formation of the (R)- or (S)-isomer of the compound of the formula I, and new intermediates II and III in optical active form obtained by the reaction steps above and wherein R.sup.2 is defined as R.sup.1 above. ##STR2##

  用立体保守方法制备化合物的(R)-或(S)-异构体，其光学纯度至少为95%，其中R.sup.1是氢原子、饱和或不饱和的较低烷基基团、环烷基基团，或基团(CH.sub.2).sub.m Ph，其中m为0-3，Ph是取代或未取代的苯基团，包括1）(R)-或(S)-脯氨酸的直接或分步O，N-二烷基化，2）氨解作用，3）还原生成化合物的(R)-或(S)-异构体的方法，以及通过上述反应步骤获得的具有光学活性形式的新中间体II和III，其中R.sup.2被定义为上述的R.sup.1。
• [EN] APIGENIN ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] ANALOGUES D'APIGÉNINE, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：ZHOU JIA

  公开号：WO2015161309A1

  公开（公告）日：2015-10-22

  Certain embodiments are directed to apigenin analogues or derivatives. In certain aspects, the derivatives are developed as cystathionine-beta-synthase (CBS) inhibitors. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents. Certain embodiments are directed methods of treating or compositions used to treat fibrosis and cancers. In certain aspects one or more compounds described herein can be administered to a subject to treat pancreatic fibrosis, liver fibrosis, pancreatic cancer, colon cancer, breast cancer, brain tumors, head/neck cancer, prostate and lung cancers as well as other inflammation.

  某些实施例涉及芹菜素类似物或衍生物。在某些方面，这些衍生物被开发为半胱氨酸β合酶（CBS）抑制剂。在某些方面，这些衍生物被用作抗癌或抗炎药物。某些实施例涉及治疗纤维化和癌症的方法或用于治疗的组合物。在某些方面，本文描述的一个或多个化合物可以被给予受试者用于治疗胰腺纤维化、肝脏纤维化、胰腺癌、结肠癌、乳腺癌、脑肿瘤、头颈癌、前列腺癌和肺癌以及其他炎症。
• Indenoisoquinolinone analogs and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20070049555A1

  公开（公告）日：2007-03-01

  The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

  本发明涉及Indenoisoquinolinone类似物，包括有效量的Indenoisoquinolinone类似物的组合物，以及用于治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血状况、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、癌症、早产并发症、心肌病、视网膜病、肾病、神经病、勃起功能障碍或尿失禁的方法，包括向需要治疗的受体内给予有效量的Indenoisoquinolinone类似物。